Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer

BACKGROUND: Liver cancer ranks third in fatalities among all cancer-related deaths. As a traditional chemotherapy drug, the application of cis-Diamminedichloroplatinum (II) (cisplatin, CDDP) for the treatment of liver cancer is greatly limited by its side effects and high drug resistance. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yunyan, Guo, Qie, Jing, Fanjing, Shang, Xiuling, Zhou, Changkai, Jing, Fanbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643970/
https://www.ncbi.nlm.nih.gov/pubmed/37969369
http://dx.doi.org/10.21037/tcr-23-435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643970/
https://www.ncbi.nlm.nih.gov/pubmed/37969369
http://dx.doi.org/10.21037/tcr-23-435

Ejemplares similares